Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma

Invest New Drugs. 2021 Feb;39(1):283-284. doi: 10.1007/s10637-020-00949-8.
No abstract available

Publication types

  • Published Erratum